What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CTX001 administered orally at the assigned cohort dose once daily for 29 days.”In the company’s words, NCT07901933 on ClinicalTrials.gov
- Tested for
- Chronic Kidney Disease, Anemia
- Main trialPhase 1
- “This is a Phase 1b, randomized, double-blinded, placebo-controlled study of CTX001 in participants with anemia and chronic kidney disease who are not on dialysis.”In the company’s words, NCT07901933 on ClinicalTrials.gov
Other drugs for Chronic Kidney Disease
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
- Migalastat HClAmicus Therapeutics · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
Coming up1
- Oct 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Oct 2027 | Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026